OPGx-LCA5

Gene therapy / editing

Phase 3underway

Evidence outlook · registrational

Leber Congenital Amaurosis: registrational readout pending

No completed mid-stage readout is on record. No upcoming registrational readout date is posted to the registry. Check News for topline announcements. The sponsor reported topline results of a Phase 1/2 study on 2025-09-30 (Positive pediatric and adult data from OPGx-LCA5 Phase 1/2 trial); that is not the registrational readout.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Leber Congenital Amaurosis

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow OPGx-LCA5 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Phase 1/2Leber Congenital AmaurosisRecruiting
Est. primary completion 2028-06-15 · NCT05616793 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2025Topline resultPositive pediatric and adult data from OPGx-LCA5 Phase 1/2 trial